RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+18.38%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$8.67B
AUM Growth
+$8.67B
(+15%)
Cap. Flow
+$213M
Cap. Flow
% of AUM
2.46%
Top 10 Holdings %
Top 10 Hldgs %
55.18%
Holding
87
New
9
Increased
9
Reduced
14
Closed
6
Top Buys
| 1 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$177M |
| 2 |
ARTV
Artiva Biotherapeutics, Inc. Common Stock
ARTV
|
$152M |
| 3 |
Vaxcyte
PCVX
|
$55.5M |
| 4 |
BIOA
BioAge Labs, Inc. Common Stock
BIOA
|
$46M |
| 5 |
IDEAYA Biosciences
IDYA
|
$42.7M |
Top Sells
| 1 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$88.9M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$75.5M |
| 3 |
Geron
GERN
|
$63.2M |
| 4 |
Ascendis Pharma
ASND
|
$59.4M |
| 5 |
UroGen Pharma
URGN
|
$51.7M |
Sector Composition
| 1 | Healthcare | 99.89% |
| 2 | Financials | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma
ASND
$11.8B
| $1.45B | 16.72% | 9,710,428 -397,972 | -4% | -$59.4M |
|
|
2
Vaxcyte
PCVX
$4B
| $993M | 11.45% | 8,689,190 +485,436 | +6% | +$55.5M |
|
3
Janux Therapeutics
JANX
$1.37B
| $416M | 4.8% | 9,165,652 | – | – |
|
4
Legend Biotech
LEGN
$6.41B
| $366M | 4.22% | 7,506,934 | – | – |
|
5
Rhythm Pharmaceuticals
RYTM
$6.85B
| $319M | 3.68% | 6,084,412 | – | – |
|
6
Avidity Biosciences
RNA
$5.99B
| $289M | 3.34% | 6,300,408 +900,000 | +17% | +$41.3M |
|
7
Tyra Biosciences
TYRA
$675M
| $245M | 2.82% | 10,416,609 | – | – |
|
8
Evolent Health
EVH
$1.12B
| $241M | 2.78% | 8,514,862 | – | – |
|
9
Edgewise Therapeutics
EWTX
$1.51B
| $238M | 2.74% | 8,909,091 | – | – |
|
10
Biogen
BIIB
$19.4B
| $230M | 2.65% | 1,184,456 +202,317 | +21% | +$39.2M |
|
11
Dyne Therapeutics
DYN
$1.92B
| $229M | 2.64% | 6,381,144 +331,940 | +5% | +$11.9M |
|
12
RxSight
RXST
$370M
| $194M | 2.23% | 3,916,825 +222,000 | +6% | +$11M |
|
|
BCAX
13
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $177M | 2.04% | +6,955,993 | New | +$177M |
|
|
CLYM
14
Climb Bio, Inc. Common Stock
CLYM
$151M
| $160M | 1.84% | 31,419,267 | – | – |
|
15
ARS Pharmaceuticals
SPRY
$1.15B
| $157M | 1.82% | 10,860,977 | – | – |
|
16
Arcellx
ACLX
$3.85B
| $155M | 1.78% | 1,851,479 +247,465 | +15% | +$20.7M |
|
|
ARTV
17
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$76.7M
| $152M | 1.76% | +9,853,302 | New | +$152M |
|
18
Wave Life Sciences
WVE
$1.53B
| $149M | 1.72% | 18,202,009 | – | – |
|
|
19
Geron
GERN
$893M
| $147M | 1.69% | 32,285,755 -13,916,670 | -30% | -$63.2M |
|
|
VRNA
20
Verona Pharma
VRNA
$9.16B
| $144M | 1.66% | 5,009,653 -2,622,993 | -34% | -$75.5M |
|
21
NewAmsterdam Pharma
NAMS
$2.71B
| $134M | 1.54% | 8,064,000 | – | – |
|
22
Apogee Therapeutics
APGE
$2.17B
| $115M | 1.33% | 1,961,863 | – | – |
|
23
Day One Biopharmaceuticals
DAWN
$769M
| $110M | 1.26% | 7,871,721 | – | – |
|
24
89bio
ETNB
$1.34B
| $105M | 1.21% | 14,175,398 | – | – |
|
25
Recursion Pharmaceuticals
RXRX
$2.04B
| $101M | 1.17% | 15,384,615 | – | – |
|